1
|
Yoshimura M, Conway-Campbell B, Ueta Y. Arginine vasopressin: Direct and indirect action on metabolism. Peptides 2021; 142:170555. [PMID: 33905792 PMCID: PMC8270887 DOI: 10.1016/j.peptides.2021.170555] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 04/12/2021] [Accepted: 04/15/2021] [Indexed: 02/07/2023]
Abstract
From its identification and isolation in 1954, arginine vasopressin (AVP) has attracted attention, not only for its peripheral functions such as vasoconstriction and reabsorption of water from kidney, but also for its central effects. As there is now considerable evidence that AVP plays a crucial role in feeding behavior and energy balance, it has become a promising therapeutic target for treating obesity or other obesity-related metabolic disorders. However, the underlying mechanisms for AVP regulation of these central processes still remain largely unknown. In this review, we will provide a brief overview of the current knowledge concerning how AVP controls energy balance and feeding behavior, focusing on physiological aspects including the relationship between AVP, circadian rhythmicity, and glucocorticoids.
Collapse
Affiliation(s)
- Mitsuhiro Yoshimura
- Department of Physiology, School of Medicine, University of Occupational and Environmental Health, Japan; Translational Health Sciences, Bristol Medical School, University of Bristol, UK.
| | | | - Yoichi Ueta
- Department of Physiology, School of Medicine, University of Occupational and Environmental Health, Japan
| |
Collapse
|
2
|
van den Akker GGH, Zacchini F, Housmans BAC, van der Vloet L, Caron MMJ, Montanaro L, Welting TJM. Current Practice in Bicistronic IRES Reporter Use: A Systematic Review. Int J Mol Sci 2021; 22:5193. [PMID: 34068921 PMCID: PMC8156625 DOI: 10.3390/ijms22105193] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 05/05/2021] [Accepted: 05/12/2021] [Indexed: 12/26/2022] Open
Abstract
Bicistronic reporter assays have been instrumental for transgene expression, understanding of internal ribosomal entry site (IRES) translation, and identification of novel cap-independent translational elements (CITE). We observed a large methodological variability in the use of bicistronic reporter assays and data presentation or normalization procedures. Therefore, we systematically searched the literature for bicistronic IRES reporter studies and analyzed methodological details, data visualization, and normalization procedures. Two hundred fifty-seven publications were identified using our search strategy (published 1994-2020). Experimental studies on eukaryotic adherent cell systems and the cell-free translation assay were included for further analysis. We evaluated the following methodological details for 176 full text articles: the bicistronic reporter design, the cell line or type, transfection methods, and time point of analyses post-transfection. For the cell-free translation assay, we focused on methods of in vitro transcription, type of translation lysate, and incubation times and assay temperature. Data can be presented in multiple ways: raw data from individual cistrons, a ratio of the two, or fold changes thereof. In addition, many different control experiments have been suggested when studying IRES-mediated translation. In addition, many different normalization and control experiments have been suggested when studying IRES-mediated translation. Therefore, we also categorized and summarized their use. Our unbiased analyses provide a representative overview of bicistronic IRES reporter use. We identified parameters that were reported inconsistently or incompletely, which could hamper data reproduction and interpretation. On the basis of our analyses, we encourage adhering to a number of practices that should improve transparency of bicistronic reporter data presentation and improve methodological descriptions to facilitate data replication.
Collapse
Affiliation(s)
- Guus Gijsbertus Hubert van den Akker
- Department of Orthopedic Surgery, Maastricht University, Medical Center+, 6229 ER Maastricht, The Netherlands; (G.G.H.v.d.A.); (B.A.C.H.); (L.v.d.V.); (M.M.J.C.)
| | - Federico Zacchini
- Department of Experimental, Diagnostic and Specialty Medicine, Bologna University, I-40138 Bologna, Italy; (F.Z.); (L.M.)
- Centro di Ricerca Biomedica Applicata—CRBA, Bologna University, Policlinico di Sant’Orsola, I-40138 Bologna, Italy
| | - Bas Adrianus Catharina Housmans
- Department of Orthopedic Surgery, Maastricht University, Medical Center+, 6229 ER Maastricht, The Netherlands; (G.G.H.v.d.A.); (B.A.C.H.); (L.v.d.V.); (M.M.J.C.)
| | - Laura van der Vloet
- Department of Orthopedic Surgery, Maastricht University, Medical Center+, 6229 ER Maastricht, The Netherlands; (G.G.H.v.d.A.); (B.A.C.H.); (L.v.d.V.); (M.M.J.C.)
| | - Marjolein Maria Johanna Caron
- Department of Orthopedic Surgery, Maastricht University, Medical Center+, 6229 ER Maastricht, The Netherlands; (G.G.H.v.d.A.); (B.A.C.H.); (L.v.d.V.); (M.M.J.C.)
| | - Lorenzo Montanaro
- Department of Experimental, Diagnostic and Specialty Medicine, Bologna University, I-40138 Bologna, Italy; (F.Z.); (L.M.)
- Centro di Ricerca Biomedica Applicata—CRBA, Bologna University, Policlinico di Sant’Orsola, I-40138 Bologna, Italy
- Programma Dipartimentale in Medicina di Laboratorio, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, I-40138 Bologna, Italy
| | - Tim Johannes Maria Welting
- Department of Orthopedic Surgery, Maastricht University, Medical Center+, 6229 ER Maastricht, The Netherlands; (G.G.H.v.d.A.); (B.A.C.H.); (L.v.d.V.); (M.M.J.C.)
| |
Collapse
|
3
|
Inhibition of Caspase-2 Translation by the mRNA Binding Protein HuR: A Novel Path of Therapy Resistance in Colon Carcinoma Cells? Cells 2019; 8:cells8080797. [PMID: 31366165 PMCID: PMC6721497 DOI: 10.3390/cells8080797] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 07/26/2019] [Accepted: 07/29/2019] [Indexed: 12/28/2022] Open
Abstract
An increased expression and cytoplasmic abundance of the ubiquitous RNA binding protein human antigen R (HuR) is critically implicated in the dysregulated control of post- transcriptional gene expression during colorectal cancer development and is frequently associated with a high grade of malignancy and therapy resistance. Regardless of the fact that HuR elicits a broad cell survival program by increasing the stability of mRNAs coding for prominent anti-apoptotic factors, recent data suggest that HuR is critically involved in the regulation of translation, particularly, in the internal ribosome entry site (IRES) controlled translation of cell death regulatory proteins. Accordingly, data from human colon carcinoma cells revealed that HuR maintains constitutively reduced protein and activity levels of caspase-2 through negative interference with IRES-mediated translation. This review covers recent advances in the understanding of mechanisms underlying HuR's modulatory activity on IRES-triggered translation. With respect to the unique regulatory features of caspase-2 and its multiple roles (e.g., in DNA-damage-induced apoptosis, cell cycle regulation and maintenance of genomic stability), the pathophysiological consequences of negative caspase-2 regulation by HuR and its impact on therapy resistance of colorectal cancers will be discussed in detail. The negative HuR-caspase-2 axis may offer a novel target for tumor sensitizing therapies.
Collapse
|
4
|
Blunsom NJ, Gomez-Espinosa E, Ashlin TG, Cockcroft S. Sustained phospholipase C stimulation of H9c2 cardiomyoblasts by vasopressin induces an increase in CDP-diacylglycerol synthase 1 (CDS1) through protein kinase C and cFos. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864:1072-1082. [PMID: 30862571 PMCID: PMC6495107 DOI: 10.1016/j.bbalip.2019.03.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 02/28/2019] [Accepted: 03/06/2019] [Indexed: 01/18/2023]
Abstract
Chronic stimulation (24 h) with vasopressin leads to hypertrophy in H9c2 cardiomyoblasts and this is accompanied by continuous activation of phospholipase C. Consequently, vasopressin stimulation leads to a depletion of phosphatidylinositol levels. The substrate for phospholipase C is phosphatidylinositol (4, 5) bisphosphate (PIP2) and resynthesis of phosphatidylinositol and its subsequent phosphorylation maintains the supply of PIP2. The resynthesis of PI requires the conversion of phosphatidic acid to CDP-diacylglycerol catalysed by CDP-diacylglycerol synthase (CDS) enzymes. To examine whether the resynthesis of PI is regulated by vasopressin stimulation, we focussed on the CDS enzymes. Three CDS enzymes are present in mammalian cells: CDS1 and CDS2 are integral membrane proteins localised at the endoplasmic reticulum and TAMM41 is a peripheral protein localised in the mitochondria. Vasopressin selectively stimulates an increase CDS1 mRNA that is dependent on protein kinase C, and can be inhibited by the AP-1 inhibitor, T-5224. Vasopressin also stimulates an increase in cFos protein which is inhibited by a protein kinase C inhibitor. We conclude that vasopressin stimulates CDS1 mRNA through phospholipase C, protein kinase C and cFos and provides a potential mechanism for maintenance of phosphatidylinositol levels during long-term phospholipase C signalling.
Collapse
Affiliation(s)
- Nicholas J Blunsom
- Dept. of Neuroscience, Physiology and Pharmacology, Division of Biosciences, University College London, London WC1E 6JJ, UK
| | - Evelyn Gomez-Espinosa
- Dept. of Neuroscience, Physiology and Pharmacology, Division of Biosciences, University College London, London WC1E 6JJ, UK
| | - Tim G Ashlin
- Dept. of Neuroscience, Physiology and Pharmacology, Division of Biosciences, University College London, London WC1E 6JJ, UK
| | - Shamshad Cockcroft
- Dept. of Neuroscience, Physiology and Pharmacology, Division of Biosciences, University College London, London WC1E 6JJ, UK.
| |
Collapse
|
5
|
Tur J, Chapalamadugu KC, Padawer T, Badole SL, Kilfoil PJ, Bhatnagar A, Tipparaju SM. Deletion of Kvβ1.1 subunit leads to electrical and haemodynamic changes causing cardiac hypertrophy in female murine hearts. Exp Physiol 2016; 101:494-508. [PMID: 27038296 DOI: 10.1113/ep085405] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 12/22/2015] [Indexed: 01/04/2023]
Abstract
NEW FINDINGS What is the central question of this study? The goal of this study was to evaluate sex differences and the role of the potassium channel β1 (Kvβ1) subunit in the heart. What is the main finding and its importance? Genetic ablation of Kvβ1.1 in females led to cardiac hypertrophy characterized by increased heart size, prolonged monophasic action potentials, elevated blood pressure and increased myosin heavy chain α (MHCα) expression. In contrast, male mice showed only electrical changes. Kvβ1.1 binds the MHCα isoform at the protein level, and small interfering RNA targeted knockdown of Kvβ1.1 upregulated MHCα. Cardiovascular disease is the leading cause of death and debility in women in the USA, and cardiac arrhythmias are a major concern. Voltage-gated potassium (Kv) channels along with the binding partners; Kvβ subunits are major regulators of the action potential (AP) shape and duration (APD). The regulation of Kv channels by the Kvβ1 subunit is unknown in female hearts. In the present study, we hypothesized that the Kvβ1 subunit is an important regulator of female cardiac physiology. To test this hypothesis, we ablated (knocked out; KO) the KCNAB1 isoform 1 (Kvβ1.1) subunit in mice and evaluated cardiac function and electrical activity by using ECG, monophasic action potential recordings and echocardiography. Our results showed that the female Kvβ1.1 KO mice developed cardiac hypertrophy, and the hearts were structurally different, with enlargement and increased area. The electrical derangements caused by Kvβ1.1 KO in female mice included long QTc and QRS intervals along with increased APD (APD20-90% repolarization). The male Kvβ1.1 KO mice did not develop cardiac hypertrophy, but they showed long QTc and prolonged APD. Molecular analysis showed that several genes that support cardiac hypertrophy were significantly altered in Kvβ1.1 KO female hearts. In particular, myosin heavy chain α expression was significantly elevated in Kvβ1.1 KO mouse heart. Using a small interfering RNA strategy, we identified that knockdown of Kvβ1 increases myosin heavy chain α expression in H9C2 cells. Collectively, changes in molecular and cell signalling pathways clearly point towards a distinct electrical and structural remodelling consistent with cardiac hypertrophy in the Kvβ1.1 KO female mice.
Collapse
Affiliation(s)
- Jared Tur
- Department of Pharmaceutical Sciences, College of Pharmacy, Tampa, FL, USA.,Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | | | - Timothy Padawer
- Department of Pharmaceutical Sciences, College of Pharmacy, Tampa, FL, USA
| | - Sachin L Badole
- Department of Pharmaceutical Sciences, College of Pharmacy, Tampa, FL, USA
| | - Peter J Kilfoil
- Diabetes and Obesity Center, University of Louisville, Louisville, KY, USA
| | - Aruni Bhatnagar
- Diabetes and Obesity Center, University of Louisville, Louisville, KY, USA
| | | |
Collapse
|
6
|
Wasilewski MA, Myers VD, Recchia FA, Feldman AM, Tilley DG. Arginine vasopressin receptor signaling and functional outcomes in heart failure. Cell Signal 2015; 28:224-233. [PMID: 26232615 DOI: 10.1016/j.cellsig.2015.07.021] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Accepted: 07/27/2015] [Indexed: 01/09/2023]
Affiliation(s)
- Melissa A Wasilewski
- Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA
| | - Valerie D Myers
- Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, USA
| | - Fabio A Recchia
- Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, USA
| | - Arthur M Feldman
- Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, USA
| | - Douglas G Tilley
- Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.
| |
Collapse
|
7
|
Serizawa K, Yogo K, Tashiro Y, Aizawa K, Ishizuka N. GATA-4 transcription factor regulates cardiac COX-2 expression induced by nicorandil in left ventricle of rats. Pharmacology 2014; 93:129-36. [PMID: 24642889 DOI: 10.1159/000360008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 01/27/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND AND AIMS Cardioprotective effects induced by delayed ischemic preconditioning and by nicorandil are mediated via expression of cardioprotective factors such as COX-2. The present study was undertaken to evaluate whether nicorandil could induce COX-2 in rats and to elucidate its mode of induction pharmacologically. METHODS AND RESULTS Three hours after administration of nicorandil (10 mg/kg, p.o.), COX-2 mRNA and protein were significantly increased in the left ventricle, although other cardioprotective factors (Bcl-2, eNOS, hexokinase, HSP, and iNOS) were not increased. This COX-2 induction in the left ventricle was preceded by induction of GATA-4, which was significant from 1 h after administration. Ventricular levels of 6-keto-prostaglandin F1α were increased 6 h after administration. Although pinacidil or isosorbide dinitrate alone did not increase COX-2 mRNA, their combined application significantly increased COX-2 mRNA. Moreover, although glibenclamide or ODQ each partly inhibited the induction of COX-2 mRNA by nicorandil, their combined application significantly inhibited it. These results suggest that nicorandil induces COX-2 protein through both the activation of KATP channels and guanylate cyclase. CONCLUSION The present study demonstrated that nicorandil induces COX-2 via GATA-4 induction in the heart through both KATP channel activation and its nitrate-like properties.
Collapse
Affiliation(s)
- Kenichi Serizawa
- Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
| | | | | | | | | |
Collapse
|
8
|
Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems. Physiol Rev 2012; 92:1813-64. [DOI: 10.1152/physrev.00035.2011] [Citation(s) in RCA: 250] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The neurohypophysial hormone arginine vasopressin (AVP) is essential for a wide range of physiological functions, including water reabsorption, cardiovascular homeostasis, hormone secretion, and social behavior. These and other actions of AVP are mediated by at least three distinct receptor subtypes: V1a, V1b, and V2. Although the antidiuretic action of AVP and V2 receptor in renal distal tubules and collecting ducts is relatively well understood, recent years have seen an increasing understanding of the physiological roles of V1a and V1b receptors. The V1a receptor is originally found in the vascular smooth muscle and the V1b receptor in the anterior pituitary. Deletion of V1a or V1b receptor genes in mice revealed that the contributions of these receptors extend far beyond cardiovascular or hormone-secreting functions. Together with extensively developed pharmacological tools, genetically altered rodent models have advanced the understanding of a variety of AVP systems. Our report reviews the findings in this important field by covering a wide range of research, from the molecular physiology of V1a and V1b receptors to studies on whole animals, including gene knockout/knockdown studies.
Collapse
Affiliation(s)
- Taka-aki Koshimizu
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Kazuaki Nakamura
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Nobuaki Egashira
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Masami Hiroyama
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Hiroshi Nonoguchi
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Akito Tanoue
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| |
Collapse
|
9
|
Abstract
Transcription factors regulate formation and function of the heart, and perturbation of transcription factor expression and regulation disrupts normal heart structure and function. Multiple mechanisms regulate the level and locus-specific activity of transcription factors, including transcription, translation, subcellular localization, posttranslational modifications, and context-dependent interactions with other transcription factors, chromatin remodeling enzymes, and epigenetic regulators. The zinc finger transcription factor GATA4 is among the best-studied cardiac transcriptional factors. This review focuses on molecular mechanisms that regulate GATA4 transcriptional activity in the cardiovascular system, providing a framework to investigate and understand the molecular regulation of cardiac gene transcription by other transcription factors.
Collapse
|
10
|
Holmes B, Artinian N, Anderson L, Martin J, Masri J, Cloninger C, Bernath A, Bashir T, Benavides-Serrato A, Gera J. Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress. Cell Signal 2011; 24:309-15. [PMID: 21964062 DOI: 10.1016/j.cellsig.2011.09.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2011] [Accepted: 09/12/2011] [Indexed: 01/12/2023]
Abstract
The A/U-rich RNA-binding protein tristetraprolin (TTP) is an mRNA destabilizing factor which plays a role in the regulated turnover of many transcripts encoding proteins involved in immune function and cell growth control. TTP also plays a role in stress-induced destabilization of mRNAs. Here we report the interaction of TTP with a component of the mTORC2 kinase, Protor-2 (PRR5-L, protein Q6MZQ0/FLJ14213/CAE45978). Protor-2 is structurally similar to human PRR5 and has been demonstrated to bind mTORC2 via Rictor and/or Sin1 and may signal downstream events promoting apoptosis. Protor-2 dissociates from mTORC2 upon hyperactivation of the kinase and is not required for mTORC2 integrity or activity. We identified Protor-2 in a yeast two-hybrid screen as a TTP interactor using the C-terminal mRNA decay domain of TTP as bait. The interaction of Protor-2 with TTP was also confirmed in vivo in co-immunoprecipitation experiments and Protor-2 was also detected in immunoprecipitates of Rictor. Protor-2 was shown to stimulate TTP-mediated mRNA turnover of several TTP-associated mRNAs (TNF-α, GM-CSF, IL-3 and COX-2) in Jurkat cells when overexpressed while the half-lives of transcripts which do not decay via a TTP-mediated mechanism were unaffected. Knockdown of Protor-2 via RNAi inhibited TTP-mediated mRNA turnover of these TTP-associated mRNAs and inhibited association of TTP with cytoplasmic stress granules (SG) or mRNA processing bodies (P-bodies) following induction of the integrated stress response. These results suggest that Protor-2 associates with TTP to accelerate TTP-mediated mRNA turnover and functionally links the control of TTP-regulated mRNA stability to mTORC2 activity.
Collapse
Affiliation(s)
- Brent Holmes
- Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California 91343, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Suzuki YJ. Cell signaling pathways for the regulation of GATA4 transcription factor: Implications for cell growth and apoptosis. Cell Signal 2011; 23:1094-9. [PMID: 21376121 PMCID: PMC3078531 DOI: 10.1016/j.cellsig.2011.02.007] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Revised: 02/12/2011] [Accepted: 02/22/2011] [Indexed: 01/28/2023]
Abstract
GATA4 is a member of the GATA family of zinc finger transcription factor, which regulates gene transcription by binding to GATA elements. GATA4 was originally discovered as a regulator of cardiac development and subsequently identified as a major regulator of adult cardiac hypertrophy. GATA4 regulates gene expression of various genes, which are involved in cardiac development and cardiac hypertrophy and heart failure. In addition to the heart, GATA4 plays important roles in the reproductive system, gastrointestinal system, respiratory system and cancer. Positive and negative regulations of GATA4 therefore are important components of biologic functions. The activation of GATA4 occurs via various cell signaling events. Earlier studies have identified protein-protein interactions of GATA4 with other factors. The discovery of interactions of GATA4 with nuclear factor for activated T cells (NFAT) revealed the importance of calcium signaling in the activation of GATA4. GATA4 can also be phosphorylated by mitogen activated protein kinases and protein kinase A. Lysine modifications also occur on the GATA4 molecule including acetylation and sumoylation. Both reactive oxygen-dependent and -independent antioxidant-sensitive pathways for GATA4 activation have also been demonstrated. The GATA4 activity is also regulated by modulating the level of GATA4 expression via transcriptional as well as translational mechanisms. This work summarizes the current understanding of regulatory mechanisms for modulating GATA4 activity.
Collapse
Affiliation(s)
- Yuichiro J Suzuki
- Department of Pharmacology, Georgetown University Medical Center, 3900 Reservoir Road NW, Washington, DC 20057, USA.
| |
Collapse
|
12
|
Komar AA, Hatzoglou M. Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle 2011; 10:229-40. [PMID: 21220943 DOI: 10.4161/cc.10.2.14472] [Citation(s) in RCA: 305] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Translation of cellular mRNAs via initiation at Internal Ribosome Entry Sites (IRESs) has received increased attention during recent years due to its emerging significance for many physiological and pathological stress conditions in eukaryotic cells. Expression of genes bearing IRES elements in their mRNAs is controlled by multiple molecular mechanisms, with IRES-mediated translation favored under conditions when cap-dependent translation is compromised. In this review, we discuss recent advances in the field and future directions that may bring us closer to understanding the complex mechanisms that guide cellular IRES-mediated expression. We present examples in which the competitive action of IRES-transacting factors (ITAFs) plays a pivotal role in IRES-mediated translation and thereby controls cell-fate decisions leading to either pro-survival stress adaptation or cell death.
Collapse
Affiliation(s)
- Anton A Komar
- Center for Gene Regulation in Health and Disease, Department of Biological, Geological and Environmental Sciences, Cleveland State University, Cleveland, OH, USA.
| | | |
Collapse
|
13
|
Barry SP, Townsend PA. What causes a broken heart--molecular insights into heart failure. INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY 2011; 284:113-79. [PMID: 20875630 DOI: 10.1016/s1937-6448(10)84003-1] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Our understanding of the molecular processes which regulate cardiac function has grown immeasurably in recent years. Even with the advent of β-blockers, angiotensin inhibitors and calcium modulating agents, heart failure (HF) still remains a seriously debilitating and life-threatening condition. Here, we review the molecular changes which occur in the heart in response to increased load and the pathways which control cardiac hypertrophy, calcium homeostasis, and immune activation during HF. These can occur as a result of genetic mutation in the case of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) or as a result of ischemic or hypertensive heart disease. In the majority of cases, calcineurin and CaMK respond to dysregulated calcium signaling and adrenergic drive is increased, each of which has a role to play in controlling blood pressure, heart rate, and left ventricular function. Many major pathways for pathological remodeling converge on a set of transcriptional regulators such as myocyte enhancer factor 2 (MEF2), nuclear factors of activated T cells (NFAT), and GATA4 and these are opposed by the action of the natriuretic peptides ANP and BNP. Epigenetic modification has emerged in recent years as a major influence cardiac physiology and histone acetyl transferases (HATs) and histone deacetylases (HDACs) are now known to both induce and antagonize hypertrophic growth. The newly emerging roles of microRNAs in regulating left ventricular dysfunction and fibrosis also has great potential for novel therapeutic intervention. Finally, we discuss the role of the immune system in mediating left ventricular dysfunction and fibrosis and ways this can be targeted in the setting of viral myocarditis.
Collapse
Affiliation(s)
- Seán P Barry
- Institute of Molecular Medicine, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland
| | | |
Collapse
|
14
|
Tsai JH, Hwang JM, Ying TH, Shyu JC, Tsai CC, Hsieh YS, Wang YW, Liu JY, Kao SH. The activation of matrix metalloproteinase-2 induced by protein kinase C alpha in decidualization. J Cell Biochem 2009; 108:547-54. [PMID: 19693770 DOI: 10.1002/jcb.22285] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
This study investigated the protein kinase C (PKC) and matrix metalloproteinase-2 (MMP-2) in the development of deciduomata in pseudo-pregnant and pregnant rats. The results showed that the expression of MMP-2 was significantly increased from day 2 to day 5 in pseudo-pregnancy and from day 7 to day 9 in pregnancy. To further investigate the correlation between MMP-2 and protein kinase C alpha (PKC alpha), the expression of MMP-2 in the 12-O-tetradecanoylphorbol 13-acetate (TPA)-treated organotypic culture of decidual tissue was determined. The results showed that the active form of MMP-2 was significantly increased in the TPA-treated cultures. Moreover, this response was inhibited by the PKC inhibitor H7, the PKC alpha specific inhibitor Gö-6976 and the translation inhibitor cycloheximide, but not by the transcription inhibitor actinomycin D or the replication inhibitor mitomycin C. In addition, TPA also reversed the MMP-2 expression after by progesterone pretreatment in the primary decidual cells. These findings indicate that PKC alpha may play an important role in the regulation of the MMP-2 expression during decidualization.
Collapse
Affiliation(s)
- Jen-Hsiang Tsai
- Department of Physical Therapy, School of Medical and Health Sciences, Fooyin University, Kaohsiung 83102, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S. Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. Circulation 2008; 118:2081-90. [DOI: 10.1161/circulationaha.108.779751] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Martina Klein
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Ralph T. Schermuly
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Peter Ellinghaus
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Hendrik Milting
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Bernd Riedl
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Sevdalina Nikolova
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Soni S. Pullamsetti
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Norbert Weissmann
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Eva Dony
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Rajkumar Savai
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Hossein A. Ghofrani
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Friedrich Grimminger
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Andreas E. Busch
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| | - Stefan Schäfer
- From Cardiology Research, Bayer Schering Pharma, Wuppertal (M.K., B.R., A.E.B., S.S.); Max-Planck Institute for Heart and Lung Research, Bad Nauheim (R.T.S.); University of Giessen Lung Center, Giessen (R.T.S., S.N., S.S.P., N.W., E.D., R.S., H.A.G., F.G.); Target Discovery, Bayer Schering Pharma, Wuppertal (P.E.); and Heart and Diabetes Center NRW, Bad Oeynhausen (H.M.), Germany
| |
Collapse
|
16
|
Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J Biol Chem 2008; 283:23274-87. [PMID: 18562319 DOI: 10.1074/jbc.m801185200] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The translation of the cyclin D1 and c-myc mRNAs occurs via internal ribosome entry site (IRES)-mediated initiation under conditions of reduced eIF-4F complex formation and Akt activity. Here we identify hnRNP A1 as an IRES trans-acting factor that regulates cyclin D1 and c-myc IRES activity, depending on the Akt status of the cell. hnRNP A1 binds both IRESs in vitro and in intact cells and enhances in vitro IRES-dependent reporter expression. Akt regulates this IRES activity by inducing phosphorylation of hnRNP A1 on serine 199. Serine 199-phosphorylated hnRNP A1 binds to the IRESs normally but is unable to support IRES activity in vitro. Reducing expression levels of hnRNP A1 or overexpressing a dominant negative version of the protein markedly inhibits rapamycin-stimulated IRES activity in cells and correlated with redistribution of cyclin D1 and c-myc transcripts from heavy polysomes to monosomes. Importantly, knockdown of hnRNP A1 also renders quiescent Akt-containing cells sensitive to rapamycin-induced G(1) arrest. These results support a role for hnRNP A1 in mediating rapamycin-induced alterations of cyclin D1 and c-myc IRES activity in an Akt-dependent manner and provide the first direct link between Akt and the regulation of IRES activity.
Collapse
Affiliation(s)
- Oak D Jo
- Department of Research and Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California 91343, USA
| | | | | | | | | | | |
Collapse
|
17
|
Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 2008; 67:11712-20. [PMID: 18089801 DOI: 10.1158/0008-5472.can-07-2223] [Citation(s) in RCA: 186] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
mTORC2 is a multimeric kinase composed of the mammalian target of rapamycin kinase (mTOR), mLST8, mSin1, and rictor. The complex is insensitive to acute rapamycin exposure and has shown functions in controlling cell growth and actin cytoskeletal assembly. mTORC2 has recently been shown to phosphorylate and activate Akt. Because approximately 70% of gliomas harbor high levels of activated Akt, we investigated whether mTORC2 activity was elevated in gliomas. In this study, we found that mTORC2 activity was elevated in glioma cell lines as well as in primary tumor cells as compared with normal brain tissue (P < 0.05). Moreover, we found that rictor protein and mRNA levels were also elevated and correlated with increased mTORC2 activity. Overexpression of rictor in cell lines led to increased mTORC2 assembly and activity. These lines exhibited increased anchorage-independent growth in soft agar, increased S-phase cell cycle distribution, increased motility, and elevated integrin beta(1) and beta(3) expression. In contrast, small interfering RNA-mediated knockdown of rictor inhibited these oncogenic activities. Protein kinase C alpha (PKC alpha) activity was shown to be elevated in rictor-overexpressing lines but reduced in rictor-knockdown clones, consistent with the known regulation of actin organization by mTORC2 via PKC alpha. Xenograft studies using these cell lines also supported a role for increased mTORC2 activity in tumorigenesis and enhanced tumor growth. In summary, these data suggest that mTORC2 is hyperactivated in gliomas and functions in promoting tumor cell proliferation and invasive potential due to increased complex formation as a result of the overexpression of rictor.
Collapse
Affiliation(s)
- Janine Masri
- Department of Research and Development, Greater Los Angeles Veterans Affairs Healthcare System, Sepulveda, California 91343-2099, USA
| | | | | | | | | | | | | |
Collapse
|